NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $1.30 -0.07 (-4.74%) Closing price 03:59 PM EasternExtended Trading$1.29 -0.02 (-1.46%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADC Therapeutics Stock (NYSE:ADCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADC Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.4150-Day Range$1.05▼$1.8752-Week Range$0.78▼$4.98Volume751,911 shsAverage Volume1.38 million shsMarket Capitalization$183.56 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview ADC Therapeutics is a biotechnology company headquartered in Epalinges, Switzerland. It develops antibody-drug conjugates (ADCs), medicines designed to use antibodies to deliver cell-killing agents to cancer cells. Its research has focused on blood cancers and solid tumors. The company’s lead product, ZYNLONTA (loncastuximab tesirine-lpyl), is an ADC that targets CD19. In the United States, it is approved for adults with relapsed or refractory large B-cell lymphoma after they have received two or more prior systemic treatments. ADC Therapeutics also develops additional ADC candidates for cancer treatment. Its work centers on refining targeted drug delivery to address cancers with limited treatment options.AI Generated. May Contain Errors. Read More ADC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreADCT MarketRank™: 2.122493520665 of 5 starsADC Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 1329th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialADC Therapeutics has a consensus price target of $5.00, representing about 283.1% upside from its current price of $1.31.Amount of Analyst CoverageADC Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.31% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 6.66.Change versus previous monthShort interest in ADC Therapeutics has recently increased by 1.39%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentADC Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for ADCT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.10% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADCT Stock News HeadlinesADC Therapeutics' Revenue Growth Outlook Remains Unclear, RBC Capital Markets SaysNovember 10, 2026 | marketscreener.comMADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9, 2026 | marketscreener.comMTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)ADC Therapeutics Q3 Product Revenue Rises 33%; Cash Runway Extends Into 2029; Stock DownNovember 9, 2026 | rttnews.comADC Therapeutics Q3 2026: ZYNLONTA Drives a Fourth Straight BeatNovember 9, 2026 | 247wallst.comADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational UpdatesNovember 9, 2026 | prnewswire.comADC Therapeutics (ADCT) Projected to Release Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comTranscript : ADC Therapeutics SA - Special CallNovember 5, 2026 | marketscreener.comMSee More Headlines ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $3.54 at the start of the year. Since then, ADCT shares have decreased by 63.1% and is now trading at $1.3050. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $21.72 million for the quarter, compared to analyst estimates of $18.70 million. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $208 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 12,245,631 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? Top institutional investors of ADC Therapeutics include Nantahala Capital Management LLC (8.94%), AIGH Capital Management LLC (3.39%), Goldman Sachs Group Inc. (2.48%) and State Street Corp (1.33%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby. View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), NIO (NIO), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Gossamer Bio (GOSS). Company Calendar Last Earnings11/09/2026Today11/19/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ADCT's financial health is in the Green zone, according to TradeSmith. ADCT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ADCT CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees191Year Founded2010Price Target and Rating Average Price Target for ADC Therapeutics$5.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+283.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.62 million Net Margins-95.73% Pretax Margin-96.20% Return on EquityN/A Return on Assets-28.26% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio2.98 Sales & Book Value Annual Sales$84.87 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value($1.77) per share Price / Book-0.74Miscellaneous Outstanding Shares140,662,000Free Float133,488,000Market Cap$183.56 million OptionableOptionable Beta1.82 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:ADCT) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.